动物造模,小鼠抑郁 z-bio 2021-11-09 280

　　Objective: To study the antidepressant effect of ginsenoside hydrolysate DS-1226 on mice with chronic sleep disorders, and to provide a scientific basis for the development of antidepressants.

　　Methods: Blank control group, model group, positive control group (paroxetine hydrochloride, 10 mg/kg), DS-1226 low-dose group (20 mg/kg), middle-dose group (40 mg/kg), 72 male ICR Mice) divided into. ), high-dose group (80 mg/kg). Except for the blank group, mice in the other groups first adapted to the roller for 3 days, and then were disturbed by sleep for 14 consecutive days. The antidepressant effect of DS-1226 was evaluated using experimental methods such as weight monitoring, autonomous activity experiment, tail suspension experiment and forced swimming experiment.

　　Result: After 14 consecutive days of sleep disturbance, compared with the blank control group, the weight of the model group was significantly reduced, and the time of tail suspension and forced swimming was significantly increased. Compared with the model group, the DS-1226 medium-dose group significantly reversed the weight loss of sleep disorders, while the other dose groups could not significantly reverse the weight loss of sleep disorders; positive drugs. Very unstable tail suspension, forced swimming time tends to decrease; DS-1226 mid-dose tail suspension time is significantly reduced, and forced swimming time is significantly reduced; tends; DS-1226 high-dose group has two The time for tail suspension and forced swimming has been greatly reduced.

　　Conclusion: DS-1226 can improve depression-like behavior in mice with chronic sleep disorders.